Magic of the Mushrooms: Effects of Psilocybin Decriminalization.
LSD
MDMA
Psilocybin reforms
policy change
psychedelics
Journal
Journal of psychoactive drugs
ISSN: 2159-9777
Titre abrégé: J Psychoactive Drugs
Pays: United States
ID NLM: 8113536
Informations de publication
Date de publication:
10 Jul 2024
10 Jul 2024
Historique:
medline:
10
7
2024
pubmed:
10
7
2024
entrez:
10
7
2024
Statut:
aheadofprint
Résumé
In the past few years, psilocybin, a psychedelic compound found in "magic mushrooms" (psilocybin mushrooms), has undergone decriminalization in numerous cities across the US and has been legalized in Oregon and Colorado. Proponents of psilocybin decriminalization have emphasized its therapeutic potential in treating mental health disorders. Furthermore, psilocybin mushrooms are considered the safest psychedelic option, with lower potency and a reduced risk of overdoses and emergency hospitalizations compared to other prevalent psychedelics, such as LSD (lysergic acid diethylamide) and MDMA (3,4-methylenedioxymethamphetamine). We analyzed the impact of psilocybin reforms on public interest in psilocybin, as well as their cross-commodity effects on LSD and MDMA, utilizing extensive web-based search data. We observe a significant increase in psilocybin search volume and a notable reduction in search volume associated with LSD and MDMA. Our results are consistent nationwide across states, irrespective of their stance on psilocybin reforms. The shift in public interest toward psilocybin, which is considered the safest psychedelic, away from LSD and MDMA, carries positive implications for public health.
Identifiants
pubmed: 38984875
doi: 10.1080/02791072.2024.2376755
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM